SUSTAIN-6

What is SUSTAIN-6?

Cardiovascular outcomes for semaglutide in type 2 diabetes at high CV risk (Marso et al., NEJM 2016): a 26% relative reduction in three-point MACE.

It confirmed what LEADER had signaled for the class.

Related reading: SUSTAIN-6: The First Semaglutide Outcomes Signal

GLP Watchdog writes these definitions from FDA labels and peer-reviewed PubMed literature.

Where SUSTAIN-6 comes up on this site

On GLP Watchdog, SUSTAIN-6 comes up in 1 research article.

Other terms under trial

• SURMOUNT-5
• SURMOUNT-2
• SURMOUNT-3
• SURPASS-2
• REWIND
• PIONEER 6
• STEP-HFpEF
• EXSCEL
• ELIXA
• AMPLITUDE-O
• HARMONY OUTCOMES
• SCALE Diabetes
• STEP 2
• SUMMIT
• SCALE Maintenance

Where the evidence lives

• The full GLP-1 glossary (150 terms, 8 categories)
• Research articles — written from primary sources
• Tools and calculators
• Compare GLP-1 telehealth providers